Trial ID or NCT#

NCT00792948

Status

not recruiting iconNOT RECRUITING

Purpose

This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

Official Title

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michaela Liedtke
Michaela Liedtke
Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist
Associate Professor of Medicine (Hematology)
Lauren Maeda
Lauren Maeda
Medical oncologist, Hematologist, Lymphoma specialist
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Caroline Berube
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
Steven Coutre
Rondeep Brar
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Cancer Clinical Trials Office
(650) 498-7061